Protalix BioTherapeutics, Inc. (FRA:PBDA)
Germany
· Delayed Price · Currency is EUR 1.460
-0.030 (-2.01%)
At close: Dec 5, 2025
Protalix BioTherapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Net Income | 5.39 | 2.93 | 8.31 | -14.93 | -27.58 | -6.52 | Upgrade
|
| Depreciation & Amortization | 1.41 | 1.3 | 1.19 | 1.09 | 1.12 | 1.3 | Upgrade
|
| Other Amortization | - | - | 0.27 | 0.3 | 2.67 | 3.47 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | -0 | 0.01 | - | -0.05 | - | Upgrade
|
| Stock-Based Compensation | 2.22 | 3.25 | 3.45 | 2.09 | 2.38 | 3.13 | Upgrade
|
| Other Operating Activities | 0.27 | 0.38 | -4.01 | -1.53 | 1.28 | -0.35 | Upgrade
|
| Change in Accounts Receivable | -12.52 | 2.32 | -0.43 | -1.19 | -1.03 | 2.09 | Upgrade
|
| Change in Inventory | -4.06 | -2.2 | -2.24 | 1.15 | -4.87 | -4.93 | Upgrade
|
| Change in Accounts Payable | -2.67 | 0.7 | 5.3 | -4.8 | 2.39 | 2.27 | Upgrade
|
| Change in Unearned Revenue | - | - | -13.18 | -7.16 | 13.23 | -26.21 | Upgrade
|
| Change in Other Net Operating Assets | -0.08 | -0 | 0.01 | -0.01 | 0.19 | -0.36 | Upgrade
|
| Operating Cash Flow | -10.03 | 8.67 | -1.32 | -25 | -10.29 | -26.11 | Upgrade
|
| Capital Expenditures | -1.66 | -1.28 | -1.15 | -0.63 | -1.46 | -0.66 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 0 | - | - | 0.05 | - | Upgrade
|
| Investment in Securities | -15 | 5.42 | -15.42 | -5 | 20 | -20 | Upgrade
|
| Other Investing Activities | 0.09 | 0.08 | -0.14 | 0.59 | 0.33 | 0.7 | Upgrade
|
| Investing Cash Flow | -16.57 | 4.22 | -16.71 | -5.04 | 18.92 | -19.95 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | - | -4.09 | - | Upgrade
|
| Long-Term Debt Repaid | - | -20.42 | - | - | -30.04 | -0.22 | Upgrade
|
| Total Debt Repaid | - | -20.42 | - | - | -34.12 | -0.22 | Upgrade
|
| Net Debt Issued (Repaid) | - | -20.42 | - | - | -34.12 | -0.22 | Upgrade
|
| Issuance of Common Stock | 12.81 | 3.63 | 24.67 | 8.24 | 46.2 | 46.68 | Upgrade
|
| Financing Cash Flow | 12.81 | -16.79 | 24.67 | 8.24 | 12.08 | 46.47 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.04 | 0.03 | -0.11 | -0.08 | 0.01 | 0.06 | Upgrade
|
| Net Cash Flow | -13.76 | -3.87 | 6.52 | -21.87 | 20.72 | 0.47 | Upgrade
|
| Free Cash Flow | -11.69 | 7.39 | -2.47 | -25.63 | -11.74 | -26.76 | Upgrade
|
| Free Cash Flow Margin | -18.91% | 13.84% | -3.77% | -53.80% | -30.62% | -42.55% | Upgrade
|
| Free Cash Flow Per Share | -0.14 | 0.09 | -0.03 | -0.53 | -0.27 | -0.92 | Upgrade
|
| Cash Interest Paid | - | 1.53 | 2.74 | 2.2 | 3.41 | 4.34 | Upgrade
|
| Cash Income Tax Paid | 1.57 | 0.39 | - | - | - | - | Upgrade
|
| Levered Free Cash Flow | -13.41 | 5.43 | -1.81 | -7.55 | -12.86 | -7.79 | Upgrade
|
| Unlevered Free Cash Flow | -12.9 | 6.1 | -0.09 | -6.27 | -10.83 | -5.22 | Upgrade
|
| Change in Working Capital | -19.32 | 0.81 | -10.54 | -12.02 | 9.9 | -27.13 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.